UK markets closed
  • NIKKEI 225

    30,168.27
    +496.57 (+1.67%)
     
  • HANG SENG

    30,074.17
    +355.93 (+1.20%)
     
  • CRUDE OIL

    63.34
    +0.12 (+0.19%)
     
  • GOLD FUTURES

    1,770.90
    -27.00 (-1.50%)
     
  • DOW

    31,312.92
    -648.94 (-2.03%)
     
  • BTC-GBP

    34,811.66
    -410.73 (-1.17%)
     
  • CMC Crypto 200

    976.25
    -18.42 (-1.85%)
     
  • ^IXIC

    13,076.81
    -521.16 (-3.83%)
     
  • ^FTAS

    3,788.74
    -6.32 (-0.17%)
     

Why FibroGen Got Mashed on Monday

Eric Volkman, The Motley Fool
·2-min read
Why FibroGen Got Mashed on Monday

On Monday, investors pushed down its stock price by 9%. The company announced that the Food and Drug Administration's (FDA) review of the company's new drug application (NDA) for roxadustat has been extended by three months. As the original action date was today, investors are coping with the one-two disappointment of FibroGen's failure to get a regulatory present in time for the holidays, and of roxadustat's inability to barrel into the new year as a marketable drug.